Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Hepatocellular 22Stomach Neoplasms 20Carcinoma, Non-Small-Cell Lung 16Colorectal Neoplasms 9Nasopharyngeal Carcinoma 5Lung Neoplasms 5Esophageal Squamous Cell Carcinoma 5Small Cell Lung Carcinoma 4Neoplasms 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Lymphoma, Extranodal NK-T-Cell 3Liver Neoplasms 3Cholangiocarcinoma 3Carcinoma, Renal Cell 3Carcinoma 3Nonsquamous Non-Small Cell Lung Cancer 2Nasopharyngeal Neoplasms 2Esophageal Neoplasms 2Carcinoma, Neuroendocrine 2Advanced Biliary Tract Cancer 2Unresectable Locally Advanced Pancreatic Cancer 1Triple Negative Breast Neoplasms 1Tislelizumab 1Thoracic Neoplasms 1Thoracic Malignancies 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Respiratory Tract Diseases 1Recurrent/ Advanced Stage Endometrial Cancer Patients 1

Interventions

Docetaxel 5Pemetrexed 4Capecitabine 4pembrolizumab 3Oxaliplatin 3icotinib 2Radiation 2Paclitaxel 2Gemcitabine 2Gefitinib 2Fluorouracil 2Drug Therapy 2Chemoradiotherapy 2Carboplatin 2sintilimab 1rucaparib 1regorafenib 1olaparib 1lenvatinib 1iron isomaltoside 1000 1ipatasertib 1iopromide 1gluconic acid 1elemene 1capecitabine-irinotecan combination 1aumolertinib 1atezolizumab 1anlotinib 1aflutinib 1XELOX 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Adenocarcinoma × sintilimab × Clear all
NCT04202601 2019-12-19

Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer

Peking University

Phase 1/2 Unknown
80 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡